Literature DB >> 33020059

In-use stability of diluted thiamazole (methimazole) infusion solutions in prefilled 0.9% sodium chloride infusion bags for continuous infusion.

André Mohr1, Irene Krämer2.   

Abstract

OBJECTIVE: In patients with severe hyperthyroidism unable to tolerate oral antithyroid therapy, diluted thiamazole infusion solutions (dose 120-240 mg) are administered by continuous infusion over 24 hours. Information about the type of diluent and compatibility/stability of the ready-to-administer thiamazole preparation is missing in the summary of product characteristics of the injection concentrate marketed in Germany. We studied the in-use stability of diluted infusion solutions over 24 hours.
METHODS: Thiamazol 40 mg inject. Henning was diluted in prefilled polyolefin infusion bags containing 250 mL 0.9% sodium chloride (NaCl) infusion solution and kept for 24 hours at room temperature and diffuse room light. Content of the diluted infusion solutions (0.48 and 0.96 mg/mL) was analysed every 4 hours over the course of 24 hours by reversed-phase high-performance liquid chromatography. pH was measured after 0, 12 and 24 hours. The infusion bags were regularly inspected for visible particles. Subvisible particles were measured by particle counting.
RESULTS: Thiamazole infusion solutions of the nominal concentrations 0.48 and 0.96 mg/mL in 0.9% NaCl diluent, kept at room temperature under diffuse room light, are physicochemically stable over a period of at least 24 hours. No evidence of colour change, particle formation or pH change was observed throughout the observation period.
CONCLUSION: Dilution of 120 or 240 mg doses of licensed thiamazole injection concentrate with 0.9% NaCl infusion solution in prefilled polyolefin containers is recommendable for continuous infusion over 24 hours in the treatment of thyrotoxicosis. © European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  administration; drug administration routes; drug compounding; emergency medicine; hospital; intravenous; pharmaceutical preparations; pharmacy service

Mesh:

Substances:

Year:  2020        PMID: 33020059      PMCID: PMC9047887          DOI: 10.1136/ejhpharm-2020-002408

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  6 in total

1.  Stability of methimazole in poloxamer lecithin organogel to determine beyond-use date.

Authors:  Alyssa Pignato; Marvin Pankaskie; Christine Birnie
Journal:  Int J Pharm Compd       Date:  2010 Nov-Dec

2.  Chromatographic methods development, validation and degradation characterization of the antithyroid drug Carbimazole.

Authors:  Maha M Abdelrahman
Journal:  Biomed Chromatogr       Date:  2019-01-30       Impact factor: 1.902

3.  Study of the British Pharmacopeia method on methimazole (thiamazole) content in carbimazole tablets.

Authors:  M Aletrari; P Kanari; D Partassides; E Loizou
Journal:  J Pharm Biomed Anal       Date:  1998-01       Impact factor: 3.935

4.  Intravenous methimazole in the treatment of refractory hyperthyroidism.

Authors:  Steven P Hodak; Caroline Huang; Donna Clarke; Kenneth D Burman; Jacqueline Jonklaas; Natasa Janicic-Kharic
Journal:  Thyroid       Date:  2006-07       Impact factor: 6.568

5.  Pharmacokinetic properties and bioavailability of methimazole.

Authors:  R Jansson; B Lindström; P A Dahlberg
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

6.  Pharmacokinetics of methimazole in normal subjects and hyperthyroid patients.

Authors:  Y Okamura; C Shigemasa; T Tatsuhara
Journal:  Endocrinol Jpn       Date:  1986-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.